Abstract
Abstract Metastatic bone disease (MBD) is a frequently encountered condition in trauma and orthopaedic practice, and delayed or inappropriate management may lead to worse oncological outcomes, dysfunction and reoperation. Updated guidance from the British Orthopaedic Oncology Society (BOOS) and British Orthopaedic Association (BOA), in 2015, aimed to raise awareness of such risks and to set clear standards for the provision of care in MBD patients. However, it is unclear whether these recommendations have been routinely adopted into clinical practice. BOOS and BOA aim to revise and update this guidance, and British Orthopaedic Association Standard for Trauma (BOAST) guidelines relating to MBD management are due to be published. The aim of this collaborative audit is to evaluate and benchmark current practice in the management of MBD prior to the publication of these BOAST guidelines, providing a baseline comparison for further future re-audit.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Surgical Protocols and Research Methodologies
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
